Request Details
Latest News

DISRUPTING ONE
OF THE LARGEST GLOBAL
HEALTHCARE MARKETS

Dialysis in end-stage renal disease

Learn more
Visionary new non-glucose based osmotic agent in peritoneal dialysis (PD). Adaptable and stable fluid elimination during both short and long dwells. Reduces metabolic stress, such as glucose and insulin spikes, and weight gain. Expected to prolong PD treatment window by slowing glucose-induced peritoneal fibrosis. Improves quality of life.
Kidney failure is a USD 80 BN highly profitable market growing at 4% p.a.
  • 25 million people worldwide are expected to suffer from kidney failure (end-stage renal disease)
  • 3rd fastest global growing cause of death
  • 11th leading global cause of death
  • Renal disease consumes 7% of U.S. Medicare budget

Global Dialysis Market Revenue

Causes of kidney failure
  • Key factors: diabetes, high blood pressure, obesity
  • High blood sugar and high blood pressure damages blood vessels and nephrons (tiny filters) in kidneys, ultimately leading to kidney failure
  • Patients with End-Stage Renal Disease (ESRD) must receive renal replacement therapy (i.e. blood filtration through dialysis or kidney transplantation) to survive
Chronic Kidney Disease ~700m patients worldwide
Kidney Failure (ESRD – end stage renal disease) ~25m patients worldwide

Treated ESRD (Dialysis)
> 2m patients worldwide

Hemodialysis (HD) ~88% of patients
Peritoneal Dialysis (PD) ~12% of patients
Transplantation ~0.5m patients in USA

Kidney Replacement Treatment

Hemodialysis (HD)

Pump and filter

1. Blood is drawn from the patient

2. Blood passes through a dialysis machine container a dialyzer

3. Dialyzer removes toxins, waste products, and extra fluid

4. Cleaned blood is returned to the patient

3-5h of Treatment in a Clinic or Hospital, 3x a Week

  • Time-consuming and limited mobility
  • Side effects: fatigue, cramps, headaches, nausea
  • Vascular access issues over time
  • Fresenius and DaVita are largest players
  • Annual cost per patient: USD 70’000*

*Global average. Source: Dialysis market – global industry trends, share, size, growth, opportunity and forecast 2022-2027, imarc report; Beaudry, et al., doi: 10.2215/CJN.10180917

Peritoneal dialysis (PD)

Soft cleaning process using the patient’s peritoneal membrane as a filter

1.  A cleansing fluid (dialysate) is introduced into the patient’s abdomen through a surgically implanted catheter.

2. The dialysate remains in the body for several hours, allowing waste products and excess fluids to pass from the blood into the solution.

3. After the dwell time, the used dialysate, now containing waste products, is drained out.

Conveniently performed at home, at work, while travelling Performed 3 times manually during the day and 1 time automatically overnight using a machine called a cycler.
  • Greater flexibility and independence
  • Less time-consuming
  • Higher first year survival rate (2-fold higher)
  • Extended treatment duration
  • Significantly better outcome for patients with heart failure (10% of dialysis patients)
  • Better preservation of kidney function, gentler on the body
  • Cost-effective: reduced need for infrastructure and personnel
  • Annual Cost per patient: USD 40’000*

HOW PERITONEAL
DIALYSIS (PD) WORKS

Filling

Dwelling

Draining

Repeats per day

PD IS THE BETTER TREATMENT OPTION, BUT HAS CURRENT LIMITATIONS, OPENING A MARKET OPPORTUNITY FOR OPTERION

Current daytime dwell solutions for PD rely on glucose, leading to metabolic health issues, specifically for diabetic patients (45% of dialysis patients).

  • Glucose Absorption: patients absorb 100-300g of glucose per day (36-110kg per year), equivalent to consuming 3-8 cans of Coca-Cola® daily.
  • Peritoneum Deterioration: the glucose load and high osmotic pressure cause serious deterioration of the peritoneum, shortening the treatment life.
  • Metabolic Impact: glucose absorption leads to weight gain and high insulin spikes, causing inflammation in the body.
  • Icodextrin® (Baxter): is based on complex polysaccharides, lacking the osmotic power required for day dwells.

OPTERION ODR IS A NON-GLUCOSE BASED OSMOTIC DRIVER FOR DAY AND NIGHT DWELLS

Fast acting, with continuous fluid elimination during day and night dwells

  • Personalized therapy due to different concentrations
  •  Reduced insulin response
  •  Novel patent-protected composition
  • Comprising Decadextrin – the Opterion new polysaccharide – and maltose
shutterstock_Freisteller-neu_214863570522 Kopie (1)
THE GAME CHANGER – OPTERION NON-GLUCOSE BASED OSMOTIC DRIVER – FOR DAY AND NIGHT DWELLS

Constant fluid elimination during short and long dwells

Group 395
  • Efficient ultrafiltration and clearance at every dwell
  • Improved patients’ quality of life

Fast acting, non-glucose-based osmotic driver

Group 395

Reduced weight gain, glucose, and insulin blood levels

Fast and efficient dialysis at reduced osmotic pressure

Group 395

Peritoneal membrane is protected and prolonges treatment duration

Flexible osmotic strength (different concentrations available)

Group 395

Optimal adaptation for patients’ dialysis needs

Polysaccharide osmotic driver with near-neutral pH

Group 395
  • Residual renal function preserved
  • No/low pain during dwell time

Less Glucose Degradation Products (GDP)

Group 395

Peritoneal membrane protected (reduced risk of peritonitis, longer PD use, preserved residual renal function)

Combination of all

  • Decreased dialysis side effects and improved quality of life
  • Prolonged PD therapy duration
  • Increasing attractivity of PD as dialysis therapy vs HD
  • Cost savings
Industry experts – who have successfully managed and exited biotech companies

Management Team

Peter Reinemer Ph.D. MBA

Chief Executive Officer

Guido Grentzmann Ph.D.

Chief Scientific Officer / Founder

Ulrike Grimm Ph.D.

Chief of Staff / Head Project Management

Maxim Voropaiev M.D.

Chief Medical Officer

Michelle Mauri, CPA

Chief Financial Officer

Mylène Fleurant M.Sc.

Head Quality Assurance

Marc Willuhn Ph.D., MBA

Head CMC / Manufacturing

Board of Directors

David Ebsworth Ph.D.

Chairman

Rice Powell, BSc

Vice Chairman

Ricardo Cordero, Ph.D.

Board Member

Jan-Anders Karlsson Ph.D.

Board Member

Mark Hahn, CPA

Board Member

Latest News

Opterion Health AG submits Clinical Trial Application for First-in-Human Study of OPT101 in Patients with Advanced Chronic Kidney Disease

Opterion Health AG submits Clinical Trial Application for First-in-Human Study of OPT101 in Patients with Advanced Chronic Kidney Disease Muttenz, Switzerland – 17 September – Opterion Health AG, a clinical-stage biopharmaceutical company developing OPT101 as an innovative treatment for patients on peritoneal dialysis (PD), today announced the submission of its Clinical Trial Application (CTA) to the European Medicines Agency (EMA). OPT101 is a novel non-glucose-based osmotic agent bringing much-needed new therapy options to patients with renal failure. The development of OPT101 represents the first innovation of its kind in over 30 years in the field of PD. The CTA submission marks a significant milestone for

Read More »
17. September 2025

Opterion Health AG Appoints Industry Leaders Rice Powell and Mark Hahn to Board of Directors

Opterion Health AG Appoints Industry Leaders Rice Powell and Mark Hahn to Board of Directors Muttenz, Switzerland, 23 June 2025 Opterion Health AG, a Swiss-based life sciences company developing a next-generation, non-glucose based peritoneal dialysis (PD) solution, today announced the appointment of two highly accomplished executives to its Board of Directors: Rice Powell, former Chairman and CEO of Fresenius Medical Care, and Mark Hahn, Chief Financial Officer of Verona Pharma and a veteran biotech finance leader. These appointments represent a significant step forward in the strategic development of Opterion Health as it prepares for clinical trials and future commercialization. Rice Powell and Mark Hahn have

Read More »
23. Juni 2025

Opterion – disrupting
one of the largest global healthcare markets

Request Details

Investor Information Request

Thank you for your interest in learning more about our investment opportunities. Please fill out the form below, and a member of our team will get back to you with the information you need.

Jan Anders Karlsson

Board Member
Dr Jan-Anders Karlsson, PhD, has 40 years of experience as a CEO and board member in pharma and biotech companies in Europe, Asia and the US. Jan-Anders was a founder and CEO of Reset Pharmaceuticals Inc, and prior to this served as CEO of Verona Pharma, a NASDAQ-listed biopharmaceutical company developing respiratory drugs. As CEO of S*BIO Pte Ltd, he focused on the discovery and development of drugs for the treatment of cancer – its product Vonjo (pacritinib) is approved in the US. Prior to S*BIO, he was Head of Pharma Global Research at Bayer Healthcare AG and held positions in Rhone-Poulenc Rorer and Astra AB. Jan-Anders received a doctorate in Medical Science (PhD) in Clinical Experimental Pharmacology from the University of Lund, Sweden.

Andreas Schmidt

Board Member

Andreas Schmid has more than 25 years of experience in Finance in the Life Sciences. He worked as a Pharma Analyst at Merrill Lynch and also has experience in fund raising as well as business development.

During the span of his career Andreas was one of the highest-ranked dialysis and generic pharma analysts, with special expertise in European and CEE/emerging markets. His coverage universe included companies such as Fresenius/FMC (Germany), Gambro (Sweden), Stada (Germany) and Aspen (South Africa). Furthermore, he played a major part in the IPOs of Zentiva (Czech Republic) and Hikma (Jordan). Andreas has also been active as a speaker at various industry conferences, for example in New York, Frankfurt, but also in Warsaw and other Eastern European countries.

In addition, Andreas works as finance lecturer at the Hochschule Pforzheim and is a board member of the German shareholder association SdK.

Ricardo Cordero

Vice Chairman
Dr Ricardo Cordero, PhD, serves as Vice Chairman of Opterion Health since 2016. Ricardo has over 30 years of experience in the Financial Services Industry where he held various senior positions, for example as CEO of BZ Bank, Managing Partner at Reichmuth & Co Investmentfonds AG, Co-founder and Co-CEO at BWO Bank, etc. Further, he is a passionate and experienced private Swiss investor and holds various investments in the Life Science, Technology and high-end Consumer Goods industry.

David Ebsworth

Chairman
Dr David Ebsworth, PhD, has been Chairman of Opterion Health since December 2016. David has over 40 years of experience in the Pharma, Healthcare and Biotech industry. David is a past CEO of Galenica, Vifor Pharma as well as Oxford GlycoSciences and past global head of the Pharmaceutical Division of Bayer. He has chaired several private and public companies and has served on numerous boards as either chairman of the audit, remuneration or nominations and governance committees. David is currently Chairman of Verona Pharma and Actimed Therapeutics.